Regulatory Affairs Syndicator

MSN MoneyCentral - In August, the Food and Drug Administration rejected an application for the company’s attention deficit hyperactivity disorder drug candidate Sparlon, which was a formulation of Provigil. The FDA rejected the application on safety grounds. Cephalon …